India Evaluates Support for AI-Driven Drug Discovery Startups

The Indian Department of Pharmaceuticals is currently assessing various support measures for startups specializing in AI-driven drug discovery, with primary focus on the regions of Bengaluru and Hyderabad. This initiative is part of the government's broader commitment to enhance pharmaceutical innovation through the integration of artificial intelligence (AI) into drug development processes. While the government has not yet unveiled a new dedicated funding program specifically for these startups, existing initiatives, such as the ₹5,000 crore Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) Scheme and the ₹10,000 crore Biopharma SHAKTI mission, lay a robust policy foundation to guide this evolution.

AI technology has the potential to transform the pharmaceutical landscape, particularly in drug discovery, clinical trials, personalized medicine, disease screening, and clinical decision support. This transition acknowledges the increasing role of AI in achieving faster and more efficient drug development processes. The recent IIMA Healthcare Summit 2026 reiterated this direction, highlighting that AI applications are already making strides in areas such as the early detection of diseases like tuberculosis and diabetic retinopathy along with enhancing decision-support systems through platforms like eSanjeevani, which has assisted over 20 crore patients.

Despite the optimistic outlook, the government has identified significant barriers that AI startups face, including access to financing, software licensing, computing resources, and specialized talent. In light of these challenges, the Department of Pharmaceuticals is considering avenues to provide assistance with software licenses and operational costs. However, details regarding the specific amounts, eligibility criteria, and timeframe for support are yet to be announced.

The ongoing support structures, including the PRIP scheme and the Biopharma SHAKTI mission, symbolize the Indian government's steadfast commitment to advancing innovation in healthcare and pharmaceuticals. The Biopharma SHAKTI mission particularly focuses on biologics, biosimilars, skilled manpower, and enhancing regulatory and clinical-trial capabilities. The alignment of AI with human clinical judgment remains a key principle for the governmental framework to ensure robust clinical validation and regulatory compliance for developed solutions.

As the government works toward expanding AI capabilities in healthcare, procurement professionals should closely monitor the evolving landscape. The potential focus on financial and operational support for AI startups is a crucial signal that may create new contracting opportunities in the biotech sector. Organizations actively engaged in AI, drug discovery, and healthcare IT are encouraged to tailor their proposals in alignment with the government's regulatory evidence requirements.

Given the geographic emphasis on Bengaluru and Hyderabad, companies operating in or around these regions might find heightened partnership and procurement opportunities as the focus intensifies on locating and supporting innovative startups. Overall, the effort to support AI-driven innovators signals a significant shift that not only promotes funding and resources for budding firms but also aims to establish India as a leading hub for pharmaceutical research — moving from the “Pharmacy of the World” to the “Laboratory of the World.” The pathway to effective AI deployment will necessitate balancing innovation with strict data safeguards and ethical considerations, ensuring that healthcare maintains its commitment to clinician accountability.

Overall, as key components of the policy framework come into fruition, procurement professionals must stay informed about the latest initiatives from the Department of Pharmaceuticals and consider how their business aligns with the evolving needs of this dynamic sector.

• The Indian government is assessing support for AI drug-discovery startups in Bengaluru and Hyderabad.
• Existing initiatives like PRIP and Biopharma SHAKTI may influence future funding avenues.
• Operational costs and software licensing are potential areas for government assistance.
• Key challenges for AI startups include access to financing and specialized talent.
• The government aims to maintain clinician accountability amid AI integration in healthcare.
• The IIMA Healthcare Summit highlighted AI's role in early disease detection and clinical decision support.